Caffeine Consumption in Glaucoma Patients and Healthy Subjects

StatusCompleted
PhaseNot applicable
SponsorWills Eye
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Final enrollment: 18 participants (planned 80)
    • Primary completion date changed from estimate of Apr 30, 2027 to Feb 16, 2024
    • Eligibility criteria expanded, about 18 words
    • Site details revised
  2. Primary completion pushed from Dec 31, 2026 to Apr 30, 2027
    • Study completion pushed from Dec 31, 2026 to Jun 30, 2027
    v12
  3. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v11
  4. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v10
  5. Primary and study completion dates pushed to Dec 31, 2024v9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Dec 31, 2021 to Oct 31, 2022
    • Study completion date: Sep 30, 2022 to Dec 31, 2022
    v8
  2. Primary completion date: Dec 30, 2020 to Dec 31, 2021
    • Study completion date: Jun 30, 2021 to Sep 30, 2022
    v7
  3. Primary completion date: Dec 30, 2019 to Dec 30, 2020
    • Study completion date: Jan 31, 2020 to Jun 30, 2021
    v6
  4. Site contact updatedv5
  5. Site contact updatedv4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  7. Start date: Sep 30, 2018 to Dec 30, 2018
    • Primary completion date: Sep 30, 2019 to Dec 30, 2019
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Wills Eye
5 trials monitored
See all monitored trials
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Trial Details
NCT Number NCT03675412
Lead Sponsor Wills Eye
Conditions
(from sponsor)		 Glaucoma, Primary Open Angle
Related terms Glaucoma, Open-Angle
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov